Aa
Family cancer
I am wondering about the younger generation in our family. My family has a strong history of cancer. Grandmother with breast cancer at 94, mother with colon cancer at age 73, uncle lung cancer, uncle stomach cancer, aunt with colon cancer, great aunt leukemia. These are all on maternal side. Brother now with prostate cancer at age 55 and me with stage 1b clear cell ovarian cancer at age 55 (no sign of disease now).
I realize with older people and cancer, the docs have always told me, well they were just old enough.to get cancer, which has always annoyed me as I have been doing medical transcription for 40 years now. With cancer hitting us at age 55 now, I am wondering if my nieces and nephews should start out being tested a little younger than is recommended for average risk cancer. Just seems like a lot of cancer in the family. Paternal side has been completely clear of cancer as far back as two generations before my father, as far as we know. There was no prostate or ovarian cancer in the family previously.
I realize with older people and cancer, the docs have always told me, well they were just old enough.to get cancer, which has always annoyed me as I have been doing medical transcription for 40 years now. With cancer hitting us at age 55 now, I am wondering if my nieces and nephews should start out being tested a little younger than is recommended for average risk cancer. Just seems like a lot of cancer in the family. Paternal side has been completely clear of cancer as far back as two generations before my father, as far as we know. There was no prostate or ovarian cancer in the family previously.
i'll outline the current United States Preventative Services Task Force (USPSTF) guidelines for screening. it's a lot, but hopefully will help.
the USPSTF could not find evidence for, or against, the use of PSA and digital rectal exam (DRE) in the overal outcome of prostate cancer. they did however find good evidence that the screening tests (PSA & DRE) can aid in early detection. they conclude that if early detection improves the outcome, then the population what benfits the most will be men 50-70 in the average risk group, and men over 45 in the increased risk group. the increased risk group is made of African American men and those men with a positive family history (first degree relative with prostate CA). the finally conclude that men with multiple medical problems, or those with a life expectancy of less than 10 years, are unlikely to benefit from screening. remember that screening also carries it's own risks versus benefits (false positives, biopsy, complications, anxiety).
the USPSTF recommends against the use of screening tests for lung cancer.
the USPSTF recommends the use of mammography every 1-2 years in women 40 and over. This can be used in conjunction with clinical breast exam, although this is not a requirement. The first mammogram may be done at 35 in women that are symptomatic or high a positive family history. The use of mammography for screening puposes is not recommended before the age of 35 due to the high density of breast tissue in this population.
furthermore, in women with a low or average risk for breast cancer the USPSTF recommends against the use of chemoprevention (tamoxifen, raloxifene) in this group. the USPSTF does, however, recommend that clinicians discuss chemoprevention in those women of high risk group. this recommendation is based on the finding that tamoxifen can significantly reduce the risk of invasive estrogen receptor positive breast cancer. less evidence was found for raloxifene. the USPSTF found good evidence that both tamoxifen and raloxifene increase the risk of thromboembolitic events (stroke, DVT, PE). they found that tamoxifen increases the risk of endometrial CA.
the USPSTF recommends screening for colon CA starting at age 50 in men and women. earlier screening recommendations depend on the patient, family history and medical conditions (ie they are different for conditions such as ulcerative colitis, etc).
the USPSTF recommends against the screening for ovarian cancer.
i wrote these off of the top of my head, so there may be some errors.
to answer your question about your nieces and nephews, the above recommendation is currently what most clinicians will follow. if genetic testing shows a susceptibility to certain cancers, that may change the management. these decisions are usually made on an individual basis.
hope it helped.
the USPSTF could not find evidence for, or against, the use of PSA and digital rectal exam (DRE) in the overal outcome of prostate cancer. they did however find good evidence that the screening tests (PSA & DRE) can aid in early detection. they conclude that if early detection improves the outcome, then the population what benfits the most will be men 50-70 in the average risk group, and men over 45 in the increased risk group. the increased risk group is made of African American men and those men with a positive family history (first degree relative with prostate CA). the finally conclude that men with multiple medical problems, or those with a life expectancy of less than 10 years, are unlikely to benefit from screening. remember that screening also carries it's own risks versus benefits (false positives, biopsy, complications, anxiety).
the USPSTF recommends against the use of screening tests for lung cancer.
the USPSTF recommends the use of mammography every 1-2 years in women 40 and over. This can be used in conjunction with clinical breast exam, although this is not a requirement. The first mammogram may be done at 35 in women that are symptomatic or high a positive family history. The use of mammography for screening puposes is not recommended before the age of 35 due to the high density of breast tissue in this population.
furthermore, in women with a low or average risk for breast cancer the USPSTF recommends against the use of chemoprevention (tamoxifen, raloxifene) in this group. the USPSTF does, however, recommend that clinicians discuss chemoprevention in those women of high risk group. this recommendation is based on the finding that tamoxifen can significantly reduce the risk of invasive estrogen receptor positive breast cancer. less evidence was found for raloxifene. the USPSTF found good evidence that both tamoxifen and raloxifene increase the risk of thromboembolitic events (stroke, DVT, PE). they found that tamoxifen increases the risk of endometrial CA.
the USPSTF recommends screening for colon CA starting at age 50 in men and women. earlier screening recommendations depend on the patient, family history and medical conditions (ie they are different for conditions such as ulcerative colitis, etc).
the USPSTF recommends against the screening for ovarian cancer.
i wrote these off of the top of my head, so there may be some errors.
to answer your question about your nieces and nephews, the above recommendation is currently what most clinicians will follow. if genetic testing shows a susceptibility to certain cancers, that may change the management. these decisions are usually made on an individual basis.
hope it helped.
MEDICAL PROFESSIONAL
What the USPTF won't tell you is that with genetic factors, earlier screening is advisable even if there's not a national preventative guideline for it that early.
For example, if a genome analysis shows increased risk of prostate cancer, UCSF genetics counselors have suggested that screening starting at age 40 may be reasonable.
There are no firm guidelines for early testing, it's a case-by-case basis. The risk of early testing is that you could have a false positive screening test, meaning that the test says you could have cancer whereas you really don't and wouldn't want to have the risk that comes with the tests to make sure you don't have cancer (which can be damaging).
For example, if a genome analysis shows increased risk of prostate cancer, UCSF genetics counselors have suggested that screening starting at age 40 may be reasonable.
There are no firm guidelines for early testing, it's a case-by-case basis. The risk of early testing is that you could have a false positive screening test, meaning that the test says you could have cancer whereas you really don't and wouldn't want to have the risk that comes with the tests to make sure you don't have cancer (which can be damaging).
You are reading content posted in the Family Health Forum
Discharge often isn't normal, and could mean an infection or an STD.
In this unique and fascinating report from Missouri Medicine, world-renowned expert Dr. Raymond Moody examines what really happens when we almost die.
Think a loved one may be experiencing hearing loss? Here are five warning signs to watch for.
When it comes to your health, timing is everything
We’ve got a crash course on metabolism basics.
Learn what you can do to avoid ski injury and other common winter sports injury.
